Newish (Beijing) Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$14.7M
- Investors
-
10
Newish (Beijing) General Information
Description
Developer of nucleic acid-based cancer therapeutics designed for early-stage treatment. The company utilizes a proprietary nucleic acid drug development platform to create targeted immunotherapy drugs, enabling the healthcare sector to access clinical-stage oncology treatments for early-stage cancer.
Contact Information
Website
www.newishes.comCorporate Office
- 1st Floor, Building B, Number 18, Xihuan South Road
- Beijing Economic and Technological Development Area
- Beijing, 100176
- China
Corporate Office
- 1st Floor, Building B, Number 18, Xihuan South Road
- Beijing Economic and Technological Development Area
- Beijing, 100176
- China
Newish (Beijing) Timeline
Newish (Beijing) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B2) | 12-Jun-2026 | $14.7M | Completed | Generating Revenue | ||
| 7. Later Stage VC | 04-Aug-2025 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B1) | 31-Mar-2025 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 01-Feb-2024 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 23-Oct-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 03-Sep-2021 | Completed | Generating Revenue | |||
| 2. Grant | 09-Aug-2021 | $463K | Completed | Generating Revenue | ||
| 1. Grant | 23-Aug-2019 | $78.7K | Completed | Generating Revenue |
Newish (Beijing) Patents
Newish (Beijing) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022434560-A1 | Use of ccl11 | Pending | 24-Jan-2022 | ||
| CA-3240773-A1 | Use of ccl11 | Pending | 24-Jan-2022 | ||
| EP-4474396-A1 | Use of ccl11 | Pending | 24-Jan-2022 | ||
| EP-4474396-A4 | Use of ccl11 | Pending | 24-Jan-2022 | ||
| US-20260159563-A1 | Use of ccl11 | Pending | 24-Jan-2022 | A61K39/39 |
Newish (Beijing) Signals
Newish (Beijing) Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kangcheng Capital | Growth/Expansion | Minority | ||
| New Frontier Group | PE/Buyout | Minority | ||
| Shanghai Zhiyue Investment Management | Growth/Expansion | Minority | ||
| Botong (Tianjin) Venture Capital | Growth/Expansion | Minority | ||
| Wuxi Capital | PE/Buyout | Minority |
Newish (Beijing) FAQs
-
When was Newish (Beijing) founded?
Newish (Beijing) was founded in 2014.
-
Where is Newish (Beijing) headquartered?
Newish (Beijing) is headquartered in Beijing, China.
-
What is the size of Newish (Beijing)?
Newish (Beijing) has 35 total employees.
-
What industry is Newish (Beijing) in?
Newish (Beijing)’s primary industry is Drug Discovery.
-
Is Newish (Beijing) a private or public company?
Newish (Beijing) is a Private company.
-
What is Newish (Beijing)’s current revenue?
The current revenue for Newish (Beijing) is .
-
How much funding has Newish (Beijing) raised over time?
Newish (Beijing) has raised $26.2M.
-
Who are Newish (Beijing)’s investors?
Kangcheng Capital, New Frontier Group, Shanghai Zhiyue Investment Management, Botong (Tianjin) Venture Capital, and Wuxi Capital are 5 of 10 investors who have invested in Newish (Beijing).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process